Safety of add-on sulfonylurea therapy in patients with type 2 diabetes using metformin: a population-based real-world study

INTRODUCTION: Metformin is the initial oral antihyperglycemic agent (OHA) of choice for most patients with type 2 diabetes (T2D). However, more than one agent is often required for optimal glucose control. As the choice of preferred second OHAs is less well defined, we sought to compare the real-wor...

Descripción completa

Detalles Bibliográficos
Autores principales: Hougen, Ingrid, Whitlock, Reid H, Komenda, Paul, Rigatto, Claudio, Clemens, Kristin K, Tangri, Navdeep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Cardiovascular and Metabolic Risk
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718392/
https://www.ncbi.nlm.nih.gov/pubmed/34969692
http://dx.doi.org/10.1136/bmjdrc-2021-002352

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718392/
https://www.ncbi.nlm.nih.gov/pubmed/34969692
http://dx.doi.org/10.1136/bmjdrc-2021-002352

Ejemplares similares